Navigation Links
Trovagene Announces Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference
Date:10/19/2013

SAN DIEGO, Oct. 14, 2013 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that two abstracts (#B175 and #B177) highlighting results from studies of the company's novel, non-invasive cancer mutation monitoring platform will be presented on October 21, 2013 at the AACR-NCI-EORTC[1] International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA.

(Logo: http://photos.prnewswire.com/prnh/20120620/LA28014LOGO)

Both studies were completed in collaboration with Dr. Filip Janku in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston. Trovagene is developing proprietary cell-free DNA urinary assays for molecular testing as a non-invasive alternative to mutation testing of tumor tissue.

The abstracts accepted for presentation during the "Molecular Classification of Tumors" poster session at the AACR-NCI-EORTC conference are:

Detection and monitoring of BRAF and KRAS mutations in cell-free urinary DNA of metastatic cancer patients by digital droplet PCR (Abstract #B175)

  • Monday, October 21, 12:30 – 3:00 p.m. and 6:30 – 7:30 p.m.
  • Location: Exhibit Hall C-D

Non-invasive tumor mutation detection of cell-free urinary DNA using massively parallel deep DNA sequencing (Abstract #B177)

  • Monday, October 21, 12:30 – 3:00 p.m. and 6:30 – 7:30 p.m.
  • Location: Exhibit Hall C-D

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its patented technology for the detection of cell-free DNA and RNA, short nucleic acid fragments originating from normal and diseased cell death that can be isolated and detected from urine. Trovagene has a strong intellectual property asset as it relates to cell-free DNA and RNA testing in urine. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2012 and other periodic reports filed with the Securities and Exchange Commission.

Contact:
Amy Caterina
Trovagene, Inc.
Investor Relations
858-952-7593
acaterina@trovagene.com

[1] American Association for Cancer Research, National Cancer Institute and European Organisation for Research and Treatment of Cancer


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Dr. Bradley Kurgis Announces Free Skin Rejuvenation Consultation
2. Extreme Peptide Announces that its EP Reward Points Program is Now Easier than Ever to Use
3. Prostate Cancer Foundation announces new urine test for prostate cancer available
4. EcoHealth Alliance announces new award from USAID to combat disease emergence and climate change
5. NIH announces awards to strengthen the biomedical research workforce
6. New York Genome Center announces the New York Stem Cell Foundation as an Associate Member
7. DiscoveRx Announces Launch of New Human Primary Cell-Based Panels for Oncology Research
8. Entomological Society of America announces 2013 awardees
9. Entomological Foundation announces 2013 Insect Science Award winners
10. Chair Mats of Glass Company Clearly Innovative Announces the Launch of 20 New Dealers in the Midwest
11. Diamond Vision Announces New and Generous Promotion on its iLASIK in NYC Procedure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: